Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Description
Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatment for cancers, atherosclerosis, and infectious diseases. The company was founded on October 11, 2000 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.01
Trade Value (12mth)
AU$1,369.00
1 week
0%
1 month
0%
YTD
-20%
1 year
-42.86%
All time high
0.55
EPS 3 yr Growth
N/A
EBITDA Margin
-23.50%
Operating Cashflow
-$2m
Free Cash Flow Return
-9.50%
ROIC
-8.50%
Interest Coverage
N/A
Quick Ratio
8.90
Shares on Issue (Fully Dilluted)
6422m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
01 July 24 |
Notification regarding unquoted securities - IVX
×
Notification regarding unquoted securities - IVX |
01 July 24 |
Change of Share Registry
×
Change of Share Registry |
01 July 24 |
Notification of cessation of securities - IVX
×
Notification of cessation of securities - IVX |
28 June 24 |
Invion secures funding through an institutional placement
×
Invion secures funding through an institutional placement |
28 June 24 |
Proposed issue of securities - IVX
×
Proposed issue of securities - IVX |
28 June 24 |
Application for quotation of securities - IVX
×
Application for quotation of securities - IVX |
28 June 24 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
07 June 24 |
Change in substantial holding
×
Change in substantial holding |
08 May 24 |
Agreement with Major South Korean Pharma Group Hanlim
×
Agreement with Major South Korean Pharma Group Hanlim |
30 April 24 |
Activities Report and Appendix 4C
×
Activities Report and Appendix 4C |
05 March 24 |
Presentation at East-West Summit in Singapore
×
Presentation at East-West Summit in Singapore |
04 March 24 |
INV043 With ICI Therapy Achieved 80% Tumour Control For ASCC
×
INV043 With ICI Therapy Achieved 80% Tumour Control For ASCC |
28 February 24 |
Appendix 4D and Half Year Financial Report
×
Appendix 4D and Half Year Financial Report |
23 February 24 |
Agreement with Dr.inB to develop Photosoft treatment for HPV
×
Agreement with Dr.inB to develop Photosoft treatment for HPV |
30 January 24 |
Activities Report and Appendix 4C
×
Activities Report and Appendix 4C |
19 January 24 |
Application for quotation of securities - IVX
×
Application for quotation of securities - IVX |
19 January 24 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
19 January 24 |
Change of Director's Interest Notice- Robert Merriel
×
Change of Director's Interest Notice- Robert Merriel |
16 January 24 |
Change of Auditor
×
Change of Auditor |
29 November 23 |
AGM Presentation
×
AGM Presentation |
29 November 23 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
29 November 23 |
Notification regarding unquoted securities - IVX
×
Notification regarding unquoted securities - IVX |
21 November 23 |
Major Milestone towards Clinical Trials
×
Major Milestone towards Clinical Trials |
30 October 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
30 October 23 |
Notification of cessation of securities - IVX
×
Notification of cessation of securities - IVX |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.